Drug polymorphism and dosage form design: a practical perspective.
about
Polymorph Impact on the Bioavailability and Stability of Poorly Soluble DrugsEnhanced NMR Discrimination of Pharmaceutically Relevant Molecular Crystal Forms through Fragment-Based Ab Initio Chemical Shift PredictionsClarithromycin dissolution enhancement by preparation of aqueous nanosuspensions using sonoprecipitation technique.Insights into atomic-level interaction between mefenamic acid and eudragit EPO in a supersaturated solution by high-resolution magic-angle spinning NMR spectroscopy.New metastable form of glibenclamide prepared by redispersion from ternary solid dispersions containing polyvinylpyrrolidone-K30 and sodium lauryl sulfate.Impact of crystal polymorphism on the systemic bioavailability of rifaximin, an antibiotic acting locally in the gastrointestinal tract, in healthy volunteers.One Polymorph and Various Morphologies of Phenytoin at a Silica Surface Due to Preparation KineticsComplex Behavior of Caffeine Crystallites on Muscovite Mica SurfacesStructural and Physicochemical Aspects of Dasatinib Hydrate and Anhydrate phases.Synthesis and antitubercular activity of 7-(R)- and 7-(S)-methyl-2-nitro-6-(S)-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazines, analogues of PA-824.Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans.Detection and characterization of altered conformations of protein pharmaceuticals using complementary mass spectrometry-based approaches.Physicomechanical characterization and optimization of EDTA-mPEG and AvicelĀ®-EDTA-mPEG in situ melt dispersion mini-pelletsEstimating the Aqueous Solubility of Pharmaceutical Hydrates.Polymorph Discrimination using Low Wavenumber Raman Spectroscopy.A Review of Disintegration Mechanisms and Measurement Techniques.Aqueous solubility of crystalline and amorphous drugs: Challenges in measurement.Ionic liquids as active pharmaceutical ingredients.Inorganic matrices: an answer to low drug solubility problem.Impact of preformulation on drug development.An overview of famotidine polymorphs: solid-state characteristics, thermodynamics, polymorphic transformation and quality control.The solid-state continuum: a perspective on the interrelationships between different solid-state forms in drug substance and drug product.Role of solvents in improvement of dissolution rate of drugs: crystal habit and crystal agglomeration.Effect of drug physico-chemical properties on the efficiency of top-down process and characterization of nanosuspension.Understanding pharmaceutical polymorphic transformations II: crystallization variables and influence on dosage forms.Why do Hydrates (Solvates) Form in Small Neutral Organic Molecules? Exploring the Crystal Form Landscapes of the Alkaloids Brucine and Strychnine.Bioequivalence Study of Warfarin in Healthy Chinese Volunteers With a Validated High-Performance Liquid Chromatography-Mass Spectrometry Method.Investigation of the Sensitivity of Transmission Raman Spectroscopy for Polymorph Detection in Pharmaceutical Tablets.Application of instrumented nanoindentation in preformulation studies of pharmaceutical active ingredients and excipients.Terahertz technology: a boon to tablet analysisMicrocrystalline preparation of akebia saponin D for its bioavailability enhancement in rats.Particular film formation of phenytoin at silica surfaces.Two ortho-rhom-bic polymorphs of hydro-morphone.Polymorphism in Commercial Sources of Fusidic Acid: A Comparative Study of the In Vitro Release Characteristics of Forms I and III from a Marketed Pharmaceutical Cream.Disintegration mediated controlled release supersaturating solid dispersion formulation of an insoluble drug: design, development, optimization, and in vitro evaluationBioavailability of indomethacin-saccharin cocrystals.Crystal engineering to improve physicochemical properties of mefloquine hydrochloride.Close intramolecular sulfur-oxygen contacts: modified force field parameters for improved conformation generation.Pharmacokinetics of carbamazepine polymorphs and dihydrate in rats, related to dogs and humans.Determination of the crystal structure of a new polymorph of theophylline.
P2860
Q26779030-384DF6AA-9840-4C9B-AB87-0DCEE22F38FEQ28822176-55C4066E-E64A-43F0-8854-858EAF799850Q30430057-D6B3A3DF-4F09-4DEA-B7BD-76EA40E31ED4Q30702880-3B7EDBBF-331B-4EE0-ABF9-1F27DF5CE836Q30922111-8EA9258F-CC68-4759-A6CB-13F2E4819CA3Q34757166-A6D25783-0A48-4216-A1EA-5BBADA9F6AD8Q35543689-1425B7C3-161C-49E9-8DCB-2E4AFA7FF664Q36032206-C61F56C5-6379-4039-9F04-157D0FDD3EBEQ36652105-CCFAE859-AEFF-4829-AE69-40A73FD4DE8DQ36691725-CE38B3DB-6CBC-4802-944D-8CE6F22D83F3Q36909306-50FD2029-9275-42E8-AAAA-CF3AC76955E3Q37065997-9EB122CE-A336-42AB-8A21-45A72349265FQ37126411-378C6867-428C-49E3-9F98-792C987DA41CQ37261680-9C7AF748-2A7B-47D3-9173-5C720CE9E46BQ37261966-3E5C03DA-5ADC-4382-BFDB-75CD28BDF9A1Q37739106-CA864A9D-1136-4933-8A21-53CB72B9F8CBQ37739476-1F100CDE-541D-476A-90A9-FEA86F2F1A98Q37873895-1B3E664B-D9A7-4E66-8946-B00FA2C14845Q38051672-D25219F6-DFD7-49BA-B0ED-CF6B1E714F47Q38093663-BB4F5174-B0A9-43DF-9B77-DC15689C442EQ38191851-40125AD2-7B33-4513-924C-097F2AD8BACCQ38239948-5B3D4AFD-AAE2-4793-9F3F-F0C77E8E3352Q38383745-83FBDA3B-3A75-4D6F-91AD-4C47BB777886Q38534116-192ECD75-2734-41A5-B578-887C6B9D510CQ38543393-7AADC182-D882-4A82-853F-60DE10C73BD3Q38697551-1F2AB899-2CDD-4E33-96F1-9DE91FE38AC9Q38858766-3962424D-49FD-418C-9581-D90390C97E2EQ38867666-D2CEDD20-B38B-47B0-B1F2-CAE0E0B9C14AQ38887909-CFE246A3-33D1-4037-876A-6669E097C669Q40405861-ED785423-78B6-4F46-ADFB-D2E083D2BBEDQ40983414-239F200F-7F35-4198-AFFE-B8B9B351BC20Q41921315-5875DC5D-73EE-49FC-BED9-D68982C53949Q42711394-ABA90FA7-E551-49EF-8FA2-399DBA348A9EQ42718244-56F6695D-4BA6-4A39-BA95-F7F3D82C45E6Q42720527-D4577EB0-F1D7-4CCB-A28C-87374D19936FQ42840455-5FB8A604-82F9-49E8-B589-096EC2FC15E7Q43119928-0DAABF83-A7E4-4F26-815E-6013A84A1C22Q44670603-B90A336D-704E-46AA-BE07-C4E2754797E8Q44883812-F45F474E-6E48-4AD7-A586-8702DC90E4C8Q46255598-7E91FBF9-5D47-433A-924D-65D68713E6CD
P2860
Drug polymorphism and dosage form design: a practical perspective.
description
2004 nĆ® lÅ«n-bĆ»n
@nan
2004幓ć®č«ę
@ja
2004幓č«ę
@yue
2004幓č«ę
@zh-hant
2004幓č«ę
@zh-hk
2004幓č«ę
@zh-mo
2004幓č«ę
@zh-tw
2004幓č®ŗę
@wuu
2004幓č®ŗę
@zh
2004幓č®ŗę
@zh-cn
name
Drug polymorphism and dosage form design: a practical perspective.
@ast
Drug polymorphism and dosage form design: a practical perspective.
@en
type
label
Drug polymorphism and dosage form design: a practical perspective.
@ast
Drug polymorphism and dosage form design: a practical perspective.
@en
prefLabel
Drug polymorphism and dosage form design: a practical perspective.
@ast
Drug polymorphism and dosage form design: a practical perspective.
@en
P1476
Drug polymorphism and dosage form design: a practical perspective.
@en
P2093
Dharmendra Singhal
William Curatolo
P304
P356
10.1016/J.ADDR.2003.10.008
P407
P577
2004-02-01T00:00:00Z